Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Juvenile Myelomonocytic Leukemia (JMML): early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Juvenile Myelomonocytic Leukemia (JMML): 4 US clinical trials tracked, none currently recruiting.
Juvenile Myelomonocytic Leukemia (JMML) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 3 of these trials.
Enrollment posture brief
Registry condition juvenile-myelomonocytic-leukemia-jmml
OPEN 0 | RECR 0% | LATE 1 | EARLY 3 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Juvenile Myelomonocytic Leukemia (JMML) has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Juvenile Myelomonocytic Leukemia (JMML) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Juvenile Myelomonocytic Leukemia (JMML) is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT02790515
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT03849651
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Diane George
NCT02061800
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
St. Jude Children's Research Hospital
NCT00186823
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Juvenile Myelomonocytic Leukemia (JMML) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Juvenile Myelomonocytic Leukemia (JMML) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Juvenile Myelomonocytic Leukemia (JMML) page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Juvenile Myelomonocytic Leukemia (JMML) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- St. Jude Children's Research Hospital sponsors the most Juvenile Myelomonocytic Leukemia (JMML) trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Juvenile Myelomonocytic Leukemia (JMML) condition card totals 4 registered trials; most-linked intervention Cyclophosphamide; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.